07.22.25 -- RNAi Vs. mRNA: Two Therapies, Two CDMO Strategies

To ensure the commercial success of cell therapies, developers must adopt innovative manufacturing and QC technologies that reduce COGS while enhancing scalability, quality, and clinical outcomes.

Addressing the complexities of viral vector manufacturing through strategic internalization, advanced technologies, and regulatory excellence is crucial for the future of gene therapies.

Explore how gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

As the cell and gene therapy sector emerged, large CDMOs ventured into the sector as if it were an easy extension of their biologics or small molecule business. It’s not. And that lack of understanding has created an industrywide bottleneck.

We illustrate how our Design of Experiment (DoE) can accelerate development timelines, lower costs, and enhance decision-making across cell therapy programs.

Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.

Gain insights into the significance of plasmid design in viral vector production and the use of analytical assays and Next-Generation Sequencing for plasmid verification.

Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.

Discover a scalable, cost-effective solution for gene therapy manufacturing with VintaProcess — featuring VintaCell, VintaFect, and fixed-bed bioreactor technology.

Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified TFDF-based manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.

Learn how our integrated Manufacturing Excellence system standardizes operations to drive continuous improvement and accelerate the delivery of medicines to patients.

Examine our innovative DOE-based strategy for developing a scalable suspension platform to produce and purify AAV vectors, optimizing consistency, productivity, and quality across scales.

The comprehensive Adenovirus Vector Lot Release Package ensures the safety of Adenovirus Vector lots through a series of rigorous assays and tests.

Observe how a one-stop solution for your cell therapy needs can help ensure efficiency, cost-effectiveness, and faster patient treatment. Our Draw-to-Thaw service streamlines the entire process.